• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆囊癌中的表观遗传学标志物。

Epigenetic Biomarkers in Gallbladder Cancer.

机构信息

Centre for Genomics, Jiwaji University, Gwalior 474011, Madhya Pradesh, India.

出版信息

Trends Cancer. 2020 Jul;6(7):540-543. doi: 10.1016/j.trecan.2020.03.003. Epub 2020 Apr 11.

DOI:10.1016/j.trecan.2020.03.003
PMID:32291238
Abstract

Gallbladder cancer (GBC) is associated with various nongenetic and genetic factors. Lack of specific and sensitive diagnostic markers has significantly impacted the mortality of this disease. Here we discuss the recent discovery of epigenetic changes that show great promise as diagnostic biomarkers as well as potential therapeutic targets for GBC.

摘要

胆囊癌(GBC)与各种非遗传和遗传因素有关。缺乏特异性和敏感性诊断标志物显著影响了该疾病的死亡率。在这里,我们讨论了最近发现的表观遗传变化,这些变化作为诊断生物标志物以及胆囊癌潜在治疗靶点具有很大的潜力。

相似文献

1
Epigenetic Biomarkers in Gallbladder Cancer.胆囊癌中的表观遗传学标志物。
Trends Cancer. 2020 Jul;6(7):540-543. doi: 10.1016/j.trecan.2020.03.003. Epub 2020 Apr 11.
2
[Targeted epigenetic therapy of cancer. Achievements and perspectives].[癌症的靶向表观遗传治疗。成就与展望]
Cir Cir. 2012 Sep-Oct;80(5):470-80.
3
Epigenetic regulation of gene expression as an anticancer drug target.表观遗传调控基因表达作为抗癌药物靶点。
Curr Cancer Drug Targets. 2011 Feb;11(2):199-212. doi: 10.2174/156800911794328510.
4
Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.组蛋白去乙酰化酶的天然产物抑制剂作为新型抗癌药物
Curr Protein Pept Sci. 2018;19(3):333-340. doi: 10.2174/1389203718666170106101133.
5
Epigenetic therapy of cancer with histone deacetylase inhibitors.用组蛋白去乙酰化酶抑制剂进行癌症的表观遗传治疗。
J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937.
6
DNA methylation as an epigenetic regulator of gallbladder cancer: An overview.DNA 甲基化作为胆囊癌的表观遗传调控因子:综述。
Int J Surg. 2018 May;53:178-183. doi: 10.1016/j.ijsu.2018.03.053. Epub 2018 Mar 27.
7
Epigenetic modulators as therapeutic targets in prostate cancer.表观遗传调节剂作为前列腺癌的治疗靶点
Clin Epigenetics. 2016 Sep 15;8:98. doi: 10.1186/s13148-016-0264-8. eCollection 2016.
8
Epigenetic transitions: towards therapeutic targets.表观遗传转变:迈向治疗靶点
Expert Opin Ther Targets. 2003 Dec;7(6):693-9. doi: 10.1517/14728222.7.6.693.
9
Melanoma epigenetics: novel mechanisms, markers, and medicines.黑色素瘤表观遗传学:新机制、标志物和药物。
Lab Invest. 2014 Aug;94(8):822-38. doi: 10.1038/labinvest.2014.87. Epub 2014 Jun 30.
10
Epigenetic Targets and their Inhibitors in Cancer Therapy.癌症治疗中的表观遗传学靶点及其抑制剂。
Curr Top Med Chem. 2018;18(28):2395-2419. doi: 10.2174/1568026619666181224095449.

引用本文的文献

1
GDF15 promotes gallbladder cancer progression by activating the NF-κB mediated Vascular Endothelial Growth Factor A (VEGFA) expression.生长分化因子15通过激活核因子κB介导的血管内皮生长因子A(VEGFA)表达促进胆囊癌进展。
Am J Cancer Res. 2025 Jun 25;15(6):2779-2793. doi: 10.62347/NAZM2261. eCollection 2025.
2
Up-regulation of thrombospondin-1 inhibits the progression of gallbladder cancer.血小板反应蛋白-1的上调抑制胆囊癌进展。
Med Oncol. 2025 Apr 21;42(5):170. doi: 10.1007/s12032-025-02719-z.
3
Super-Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription-Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer.
由SOX9和TCF7L2驱动的超级增强子重编程代表了治疗胆囊癌的转录靶向治疗弱点。
Adv Sci (Weinh). 2024 Dec;11(47):e2406448. doi: 10.1002/advs.202406448. Epub 2024 Nov 4.
4
A prognostic model and novel risk classification system for radical gallbladder cancer surgery: A population-based study and external validation.根治性胆囊癌手术的预后模型和新型风险分类系统:一项基于人群的研究及外部验证
Heliyon. 2024 Aug 2;10(15):e35551. doi: 10.1016/j.heliyon.2024.e35551. eCollection 2024 Aug 15.
5
Potential Molecular Markers for Cholecystic Inflammation-Induced Carcinogenesis Based on RNA-Seq Gene Screening.基于RNA测序基因筛选的胆囊炎症诱导癌变的潜在分子标志物
Comb Chem High Throughput Screen. 2025;28(6):931-943. doi: 10.2174/0113862073287686240409082130.
6
Structural Basis of Targeted Imaging and Therapy in Cancer Explorations with the Epigenetic Drugs.癌症探索中的靶向成像和治疗的结构基础:表观遗传药物的应用。
Subcell Biochem. 2022;100:503-521. doi: 10.1007/978-3-031-07634-3_15.
7
Ubiquitin-specific protease 3 facilitates cell proliferation by deubiquitinating pyruvate kinase L/R in gallbladder cancer.泛素特异性蛋白酶 3 通过去泛素化丙酮酸激酶 L/R 促进胆囊癌中的细胞增殖。
Lab Invest. 2022 Dec;102(12):1367-1376. doi: 10.1038/s41374-022-00836-1. Epub 2022 Sep 30.
8
Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.胆道癌中常见的 DNA 甲基化变化可识别具有不同免疫特征和临床结局的亚型。
BMC Med. 2022 Feb 7;20(1):64. doi: 10.1186/s12916-021-02197-w.
9
Primary Hepatoid Adenocarcinoma of Gallbladder With MB21D2/GALNT12/ARID2 Mutations: A Case Report.胆囊原发性肝样腺癌伴 MB21D2/GALNT12/ARID2 基因突变:一例报告。
Front Endocrinol (Lausanne). 2022 Jan 3;12:791153. doi: 10.3389/fendo.2021.791153. eCollection 2021.
10
ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation.ARRB1通过促进TAK1/MAPK信号激活驱动胆囊癌进展。
J Cancer. 2021 Jan 30;12(7):1926-1935. doi: 10.7150/jca.53325. eCollection 2021.